JP7500037B2 - 血中尿酸値低下剤及び血中尿酸値低下用食品組成物 - Google Patents
血中尿酸値低下剤及び血中尿酸値低下用食品組成物 Download PDFInfo
- Publication number
- JP7500037B2 JP7500037B2 JP2019136151A JP2019136151A JP7500037B2 JP 7500037 B2 JP7500037 B2 JP 7500037B2 JP 2019136151 A JP2019136151 A JP 2019136151A JP 2019136151 A JP2019136151 A JP 2019136151A JP 7500037 B2 JP7500037 B2 JP 7500037B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- oxo
- uric acid
- fatty acids
- blood uric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims description 66
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims description 66
- 229940116269 uric acid Drugs 0.000 title claims description 66
- 210000004369 blood Anatomy 0.000 title claims description 43
- 239000008280 blood Substances 0.000 title claims description 43
- 239000003795 chemical substances by application Substances 0.000 title claims description 25
- 235000013305 food Nutrition 0.000 title claims description 16
- 239000000203 mixture Substances 0.000 title claims description 12
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 51
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 51
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 claims description 25
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 claims description 21
- 150000002148 esters Chemical class 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 14
- -1 9-oxo-10E Chemical compound 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 9
- PMTMAFAPLCGXGK-UHFFFAOYSA-N OPDA Natural products CCC=CCC1C(CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-UHFFFAOYSA-N 0.000 claims description 8
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- PMTMAFAPLCGXGK-JMTMCXQRSA-N (15Z)-12-oxophyto-10,15-dienoic acid Chemical compound CC\C=C/C[C@H]1[C@@H](CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-JMTMCXQRSA-N 0.000 claims description 6
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 6
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- 230000029142 excretion Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 5
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 claims description 4
- BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 claims description 4
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 claims description 4
- KSIRMUMXJFWKAC-FHJHOUOTSA-N prostaglandin A3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O KSIRMUMXJFWKAC-FHJHOUOTSA-N 0.000 claims description 4
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 claims description 3
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 claims description 3
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims description 3
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 claims description 3
- HVGRZDASOHMCSK-UHFFFAOYSA-N (Z,Z)-13,16-docosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-UHFFFAOYSA-N 0.000 claims description 3
- JVDHPAUNFBGCFT-CWWKMNTPSA-N 12Z,15Z-Octadecadienoic acid Chemical compound CC\C=C/C\C=C/CCCCCCCCCCC(O)=O JVDHPAUNFBGCFT-CWWKMNTPSA-N 0.000 claims description 3
- KLLGGGQNRTVBSU-FQSPHKRJSA-N 13(S)-HOTrE Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/CCCCCCCC(O)=O KLLGGGQNRTVBSU-FQSPHKRJSA-N 0.000 claims description 3
- HNBLUNXZQNJFRB-KYLWABQHSA-N 13S-HOTrE(gamma) Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/CCCCC(O)=O HNBLUNXZQNJFRB-KYLWABQHSA-N 0.000 claims description 3
- SZVNKXCDJUBPQO-DWMAKUKJSA-N 6-{(1S,5S)-4-oxo-5-[(2Z)-pent-2-en-1-yl]cyclopent-2-en-1-yl}hexanoic acid Chemical compound CC\C=C/C[C@H]1[C@@H](CCCCCC(O)=O)C=CC1=O SZVNKXCDJUBPQO-DWMAKUKJSA-N 0.000 claims description 3
- RIGGEAZDTKMXSI-MEBVTJQTSA-N 9(S)-HOTrE Chemical compound CC\C=C/C\C=C/C=C/[C@@H](O)CCCCCCCC(O)=O RIGGEAZDTKMXSI-MEBVTJQTSA-N 0.000 claims description 3
- LUZSWWYKKLTDHU-ZJHFMPGASA-N 9-oxo-ODE Chemical compound CCCCC\C=C/C=C/C(=O)CCCCCCCC(O)=O LUZSWWYKKLTDHU-ZJHFMPGASA-N 0.000 claims description 3
- PMTMAFAPLCGXGK-TTXFDSJOSA-N 9s,13r-12-Oxophytodienoic Acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-TTXFDSJOSA-N 0.000 claims description 3
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims description 3
- 235000021297 Eicosadienoic acid Nutrition 0.000 claims description 3
- HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 claims description 3
- CUXYLFPMQMFGPL-FWSDQLJQSA-N alpha-Eleostearic acid Natural products CCCCC=CC=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-FWSDQLJQSA-N 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- IXLCRBHDOFCYRY-UHFFFAOYSA-N dioxido(dioxo)chromium;mercury(2+) Chemical compound [Hg+2].[O-][Cr]([O-])(=O)=O IXLCRBHDOFCYRY-UHFFFAOYSA-N 0.000 claims description 3
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 claims description 3
- YEXZTHNGURCFSJ-UHFFFAOYSA-N henicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=CC(O)=O YEXZTHNGURCFSJ-UHFFFAOYSA-N 0.000 claims description 3
- 229940086319 nattokinase Drugs 0.000 claims 2
- 108010073682 nattokinase Proteins 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 35
- 239000000194 fatty acid Substances 0.000 description 35
- 229930195729 fatty acid Natural products 0.000 description 35
- 150000004665 fatty acids Chemical class 0.000 description 31
- 150000004671 saturated fatty acids Chemical class 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 25
- 235000003441 saturated fatty acids Nutrition 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 239000012124 Opti-MEM Substances 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 102000056457 human SLC22A12 Human genes 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940083914 URAT1 inhibitor Drugs 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 description 2
- ZUUFLXSNVWQOJW-MBIXAETLSA-N (2e,4e,6e)-octadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C(O)=O ZUUFLXSNVWQOJW-MBIXAETLSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- AVKOENOBFIYBSA-WMPRHZDHSA-N (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O AVKOENOBFIYBSA-WMPRHZDHSA-N 0.000 description 1
- JHXAZBBVQSRKJR-PMALLSHNSA-N (9E,11Z)-13-oxo-9,11-octadecadienoic acid Natural products CCCCCC(=O)C=C/C=C/CCCCCCCC(=O)O JHXAZBBVQSRKJR-PMALLSHNSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JHXAZBBVQSRKJR-BSZOFBHHSA-N 13-oxo-9Z,11E-ODE Chemical compound CCCCCC(=O)\C=C\C=C/CCCCCCCC(O)=O JHXAZBBVQSRKJR-BSZOFBHHSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-DOMIDYPGSA-N 7,9-dihydro-3H-purine-2,6,8-trione Chemical compound N1C(=O)NC=2N[14C](=O)NC=2C1=O LEHOTFFKMJEONL-DOMIDYPGSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 108091006745 SLC22A12 Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 101710102931 Solute carrier family 22 member 12 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000021288 n-6 DPA Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(1)試験サンプル溶液の調製
表1~3に示す飽和脂肪酸及び不飽和脂肪酸、並びに陽性対照としてURAT1阻害薬として既知であるベンズブロマロン(benzbromarone)(Wako社製)をDMSOに溶解し、目的濃度の100-1000倍となるようにDMSOを用いて希釈した。14Cで標識された尿酸([8-14C]-Uric Acid:ARC0513、American Radiolabeled Chemicals,Inc製)は、125mMグルコン酸ナトリウム、4.8mMグルコン酸カリウム、1.2mM硫酸マグネシウム、1.3mMグルコン酸カルシウム、1.2mMリン酸2水素カリウム、25mMヘペス及び5mMグルコース(pH7.4)をそれぞれ最終濃度として含有し、Clを含まないHanks平衡塩溶液(以下、HBSS Cl(-)とする)を用いて希釈し、最終濃度5μMとなるように調製した。この14C標識尿酸溶液を用いて試験サンプルを100~1000倍希釈し、目的濃度となるように調製したものをサンプル溶液(飽和脂肪酸:100μM、不飽和脂肪酸:20μM)とした。なお、試験サンプルを含まない0.1~1%DMSO溶液をコントロールとした。
ヒト胎児腎細胞由来293A細胞(Invitrogen社製)3.5×105cells/mLを10%ウシ胎児血清を含むDMEM培地(ナカライテスク社製)に懸濁し、12ウェルプレートに1mL/well播種したのち、37℃の5%CO2インキュベータ内で1日間培養した。滅菌MilliQにより1mg/mLに調製したポリエチレンイミン“MAX”(Polysciences社製)を1ウェルあたり3.75μLとり、50μLのOptiMEM(Invitrogen社製)で希釈したのち室温で5分間静置した(以下、「PEI-OptiMEM」とする。)。1ウェルあたり0.75μg(例えば0.2μg/μLに調製したプラスミド溶液を3.75μL)のヒトURAT1発現ベクター及びヒトURAT1の導入されていないコントロールベクターを50μLのOptiMEMで希釈し、室温で5分間静置した(以下、「Plasmid-OptiMEM」とする。)。Plasmid-OptiMEM及びPEI-OptiMEMを混合し、室温にて20分以上放置したのち、1ウェルあたり107.5μLずつ293A細胞に添加した。293A細胞は37℃の5%CO2インキュベータ内で2日間培養し、尿酸取り込み阻害活性試験に供した。
以下の試験は37℃に加温したホットプレート上にて行った。(2)で用意した細胞を含む各ウェルから培地を吸引除去した後、HBSS Cl(-)を用いて各ウェルを洗ったのち、500μLのHBSS Cl(-)で置換し、37℃の5%CO2インキュベータ内で約10分間プレインキュベーションした。HBSS Cl(-)を吸引除去した後、予め37℃に加温した(1)のサンプル溶液を500μL添加し、20秒間取り込み反応を行った。反応終了後、サンプル溶液を直ちに吸引除去し、氷冷したHBSS Cl(-)で洗浄した。細胞を1ウェルあたり500μLの0.2N水酸化ナトリウム水溶液を用いて氷上にて溶解し、100μLの1N塩酸で中和した後、液体シンチレーション計測用バイアル(東京硝子社製)に400μL移した。5mLのクリアゾルII(nacalai社製)と混合したのち、液体シンチレーションカウンター(PerkinElmer社製)にて放射活性(壊変数)を測定した。また、細胞溶解液20μLを用いて、PIERCE BCA Protein assay kit(サーモフィッシャー社製)によりタンパク質濃度を定量した。試験化合物存在下におけるURAT1特異的尿酸輸送活性率は、測定された放射活性(壊変数)の値を用いて、下記のように算出した。
URAT1特異的尿酸輸送活性率(%)=[(A-C)/(B-C)]×100
A:ヒトURAT1一過性発現細胞にサンプル溶液を添加した場合の輸送活性
B:ヒトURAT1一過性発現細胞に0.1~1%DMSO溶液を添加した場合の輸送活性
C:コントロールベクターを導入した細胞に0.1~1%DMSO溶液を添加した場合の輸送活性
ここで、A、B及びCの各輸送活性は、下記のように算出した。
A、B及びCの各輸送活性[μL/mg/min]=X/(Y×Z)
X:600μL細胞溶解中和液における細胞に取り込まれた14Cで標識された尿酸の壊変数[DPM/600μL/min]
Y:細胞中のタンパク量[mg/600μL]
Z:取り込み実験に使用した反応混液の単位量当たりにおける、14Cで標識された尿酸の壊変数[DPM/1μL]
Claims (4)
- 不飽和脂肪酸、又はその塩若しくはエステル(但し、ジグリセリドを除く。)を有効成分として含有し、
前記不飽和脂肪酸が、α-エレオステアリン酸、エイコサジエン酸、エイコサトリエン酸、ω-3アラキドン酸、ω-6アラキドン酸、ヘニコサペンタエン酸、ドコサジエン酸、ドコサテトラエン酸、ω-3ドコサペンタエン酸、ω-6ドコサペンタエン酸、12-オキソ-フィトジエン酸、13-epi-12-オキソ-フィトジエン酸、dinor-12-オキソ-フィトジエン酸、プロスタグランジンA1、プロスタグランジンA2、プロスタグランジンA3、13-オキソ-9Z,11E-オクタデカジエン酸、9-オキソ-10E,12Z-オクタデカジエン酸、9-オキソ-10E,12Z,15Z-オクタデカジエン酸、9S-ヒドロキシ-10E,12Z,15Z-オクタデカトリエン酸、13S-ヒドロキシ-6Z,9Z,11E-オクタデカトリエン酸及び13S-ヒドロキシ-9Z,11E,15Z-オクタデカトリエン酸から選択されるものである、血中尿酸値低下剤(但し、ナットーキナーゼを含有するものを除く。)。 - 尿酸***促進作用に基づくものである、請求項1に記載の血中尿酸値低下剤。
- URAT1阻害作用に基づくものである、請求項2に記載の血中尿酸値低下剤。
- 不飽和脂肪酸、又はその塩若しくはエステル(但し、ジグリセリドを除く。)を有効成分として含有し、
前記不飽和脂肪酸が、α-エレオステアリン酸、エイコサジエン酸、エイコサトリエン酸、ω-3アラキドン酸、ω-6アラキドン酸、ヘニコサペンタエン酸、ドコサジエン酸、ドコサテトラエン酸、ω-3ドコサペンタエン酸、ω-6ドコサペンタエン酸、12-オキソ-フィトジエン酸、13-epi-12-オキソ-フィトジエン酸、dinor-12-オキソ-フィトジエン酸、プロスタグランジンA1、プロスタグランジンA2、プロスタグランジンA3、13-オキソ-9Z,11E-オクタデカジエン酸、9-オキソ-10E,12Z-オクタデカジエン酸、9-オキソ-10E,12Z,15Z-オクタデカジエン酸、9S-ヒドロキシ-10E,12Z,15Z-オクタデカトリエン酸、13S-ヒドロキシ-6Z,9Z,11E-オクタデカトリエン酸及び13S-ヒドロキシ-9Z,11E,15Z-オクタデカトリエン酸から選択されるものである、血中尿酸値低下用食品組成物(但し、ナットーキナーゼを含有するものを除く。)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019136151A JP7500037B2 (ja) | 2019-07-24 | 2019-07-24 | 血中尿酸値低下剤及び血中尿酸値低下用食品組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019136151A JP7500037B2 (ja) | 2019-07-24 | 2019-07-24 | 血中尿酸値低下剤及び血中尿酸値低下用食品組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021020855A JP2021020855A (ja) | 2021-02-18 |
JP7500037B2 true JP7500037B2 (ja) | 2024-06-17 |
Family
ID=74574154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019136151A Active JP7500037B2 (ja) | 2019-07-24 | 2019-07-24 | 血中尿酸値低下剤及び血中尿酸値低下用食品組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7500037B2 (ja) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001278786A (ja) | 2000-03-29 | 2001-10-10 | Morinaga Milk Ind Co Ltd | 高尿酸性疾患予防治療剤 |
WO2004022049A1 (ja) | 2002-09-05 | 2004-03-18 | The Nisshin Oillio Group, Ltd. | 痩身剤およびその飲食物 |
JP2006151952A (ja) | 2004-11-05 | 2006-06-15 | Oto Corporation:Kk | 高脂血症乃至高尿酸血症改善剤、及び、健康食品 |
WO2006123550A1 (ja) | 2005-05-16 | 2006-11-23 | Nippon Suisan Kaisha, Ltd. | 炎症性疾患予防又は治療剤 |
WO2009086614A1 (en) | 2008-01-08 | 2009-07-16 | Albert Knab | Method and application of synbiotic food/feed composition for humans and animals |
WO2009151094A1 (ja) | 2008-06-11 | 2009-12-17 | 株式会社リコム | ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品 |
US20100291053A1 (en) | 2003-06-23 | 2010-11-18 | Diane Clayton | Inflammatory Disease Treatment |
JP2011116680A (ja) | 2009-12-02 | 2011-06-16 | Nippon Suisan Kaisha Ltd | 生活習慣病予防又は改善剤 |
WO2012060718A1 (en) | 2010-11-05 | 2012-05-10 | Sally Diana Poppitt | Preventing or treating metabolic syndrome by administering a trans fatty acid, or a salt, ester or precursor thereof, or sialic acid in free or bound form |
WO2016117057A1 (ja) | 2015-01-21 | 2016-07-28 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
JP2017516823A (ja) | 2014-06-04 | 2017-06-22 | ディグニティ サイエンシス リミテッド | Dglaを含む薬学的組成物及びその使用 |
CN108743592A (zh) | 2018-08-24 | 2018-11-06 | 青岛大学 | B族维生素或ω脂肪酸在调节体内尿酸水平中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0826988A (ja) * | 1994-07-13 | 1996-01-30 | Kao Corp | ケトン体尿中***促進剤 |
-
2019
- 2019-07-24 JP JP2019136151A patent/JP7500037B2/ja active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001278786A (ja) | 2000-03-29 | 2001-10-10 | Morinaga Milk Ind Co Ltd | 高尿酸性疾患予防治療剤 |
WO2004022049A1 (ja) | 2002-09-05 | 2004-03-18 | The Nisshin Oillio Group, Ltd. | 痩身剤およびその飲食物 |
US20100291053A1 (en) | 2003-06-23 | 2010-11-18 | Diane Clayton | Inflammatory Disease Treatment |
JP2006151952A (ja) | 2004-11-05 | 2006-06-15 | Oto Corporation:Kk | 高脂血症乃至高尿酸血症改善剤、及び、健康食品 |
WO2006123550A1 (ja) | 2005-05-16 | 2006-11-23 | Nippon Suisan Kaisha, Ltd. | 炎症性疾患予防又は治療剤 |
WO2009086614A1 (en) | 2008-01-08 | 2009-07-16 | Albert Knab | Method and application of synbiotic food/feed composition for humans and animals |
WO2009151094A1 (ja) | 2008-06-11 | 2009-12-17 | 株式会社リコム | ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品 |
JP2011116680A (ja) | 2009-12-02 | 2011-06-16 | Nippon Suisan Kaisha Ltd | 生活習慣病予防又は改善剤 |
WO2012060718A1 (en) | 2010-11-05 | 2012-05-10 | Sally Diana Poppitt | Preventing or treating metabolic syndrome by administering a trans fatty acid, or a salt, ester or precursor thereof, or sialic acid in free or bound form |
JP2017516823A (ja) | 2014-06-04 | 2017-06-22 | ディグニティ サイエンシス リミテッド | Dglaを含む薬学的組成物及びその使用 |
WO2016117057A1 (ja) | 2015-01-21 | 2016-07-28 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
CN108743592A (zh) | 2018-08-24 | 2018-11-06 | 青岛大学 | B族维生素或ω脂肪酸在调节体内尿酸水平中的应用 |
Non-Patent Citations (2)
Title |
---|
Annals of Nutrition and Metabolism,2010年,Vol.56, No.3,pp.170-175 |
Polish Journal of Food and Nutrition Sciences,2008年,Vol.58, No.3,pp.389-395 |
Also Published As
Publication number | Publication date |
---|---|
JP2021020855A (ja) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2992836B2 (ja) | 共役リノール酸の投与による動物の体脂肪を減少させる方法 | |
EP1237545B1 (en) | Use of stearidonic acid in the manufacture of a medicament for the treatment or prevention of cancer | |
JP2020182497A (ja) | 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 | |
KR101245364B1 (ko) | 혈관의 노화에 기인하는 증상 또는 질환을 예방 또는 완화하는 작용이 있는 조성물 | |
JP7500037B2 (ja) | 血中尿酸値低下剤及び血中尿酸値低下用食品組成物 | |
JP6750831B2 (ja) | 非アルコール性脂肪性肝疾患の処置 | |
JP2006306813A (ja) | 肥満細胞増殖抑制剤 | |
JP2018104372A (ja) | クリルオイルと魚油とシソ油とを含有する組成物 | |
JPWO2007040006A1 (ja) | ペルオキシソーム増殖剤応答性受容体PPARγ活性化剤、および該活性化剤を含有する特定症状の予防または改善用組成物 | |
JP2017052747A (ja) | ウロプラキン発現促進剤 | |
US7579374B2 (en) | Agent for improving bone metabolism | |
JP2007217311A (ja) | 神経細胞分化誘導剤 | |
JP6067558B2 (ja) | 恐怖記憶の軽減方法 | |
JP2011256133A (ja) | Sr−b1タンパク質発現亢進剤 | |
WO2018066394A1 (ja) | 筋肉を柔軟にするための組成物 | |
JP2017061436A (ja) | 血中尿酸値低下剤 | |
JP6824506B2 (ja) | 脂質組成物 | |
JPS63258816A (ja) | 抗癌剤組成物 | |
JP4594489B2 (ja) | 特異的殺癌細胞剤及びこれを配合してなる組成物 | |
JP3917825B2 (ja) | 血管新生抑制剤 | |
WO2023157948A1 (ja) | 経口用組成物 | |
JP7099821B2 (ja) | Pcsk9阻害剤及びコレステロール代謝改善用食品組成物 | |
JP2019172614A (ja) | 遺伝子発現制御剤及び筋委縮の抑制剤、予防剤又は改善剤 | |
JP7426213B2 (ja) | 栄養組成物 | |
JP7506473B2 (ja) | アミロイドβ蓄積抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20201007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201007 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220719 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230501 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230501 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240529 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7500037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |